glp-1 cv outcome trials receptor agonists were developed for glycemic control. The cardiovascular data has since reframed how cardiologists need to think about this drug class entirely. Across LEADER, SUSTAIN-6, REWIND, and SELECT, GLP-1 The Big Trial of a

Rogan has named BPC-157, TB-500, thymosin, and ipamorelin with CJC-1295, all alongside testosterone replacement therapy and all under medical supervision (source)

Experience the power of Acetyl L-Carnitine superior memory, performance, energy, cognitive and cardiovascular support

En caso de patologa crnica (renal, cardaca, tiroidea), embarazo, lactancia o toma de medicamentos, consulta a tu mdico antes de comenzar una cura de L-carnitina

doi: 10.3390/pathophysiology30030032 32

Funding Open access funding provided by Universit degli Studi di Napoli Federico II within the CRUI-CARE Agreement

low-dose NAMPT inhibition with FK866 can alleviate age-related cognitive impairment by enhancing autophagy and reducing neuroinflammation 219